A randomized, double-blind, parallel-group, placebo-controlled, dose-response, multicentre, multinational study evaluating the efficacy and safety of AVE2268 administered either twice daily (breakfast and lunch) at a dose of 300, 600 and 1200 mg or once daily (breakfast) at a dose of 1200 mg, in patients with type 2 diabetes treated with metformin and not adequately controlled

Trial Profile

A randomized, double-blind, parallel-group, placebo-controlled, dose-response, multicentre, multinational study evaluating the efficacy and safety of AVE2268 administered either twice daily (breakfast and lunch) at a dose of 300, 600 and 1200 mg or once daily (breakfast) at a dose of 1200 mg, in patients with type 2 diabetes treated with metformin and not adequately controlled

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs AVE 2268 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jul 2009 Actual patient number (317) added, additional trial locations Australia and Belgium added as reported by ClinicalTrials.gov.
    • 31 Oct 2008 Sanaofi-aventis has decided to discontiune development of AVE-2268 according to media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top